Get the Stockscreener App
44.86
2.16%
-0.99
After Hours:
44.86
Akero Therapeutics Inc Stock (AKRO) Latest News
Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) CEO Sells 30,000 Shares of Stock - MarketBeat
Akero Therapeutics (NASDAQ:AKRO) Stock Price Up 5.5%Here's What Happened - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives $76.29 Consensus Target Price from Brokerages - MarketBeat
Akero Therapeutics CEO Andrew Cheng sells $1.25 million in stock - Investing.com India
Proficio Capital Partners LLC Acquires Shares of 11,490 Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World
Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Timothy Rolph Sells 12,500 Shares - MarketBeat
Q1 EPS Estimate for Akero Therapeutics Boosted by Analyst - MarketBeat
Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Sells 50,000 Shares of Stock - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Sells $48,090.00 in Stock - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Stake Decreased by Y Intercept Hong Kong Ltd - MarketBeat
Trading (AKRO) With Integrated Risk Controls - Stock Traders Daily
Akero therapeutics chief scientific officer sells $556,590 in stock By Investing.com - Investing.com Australia
Akero therapeutics chief scientific officer sells $556,590 in stock - Investing.com
Akero Therapeutics, Inc. (NASDAQ:AKRO) Short Interest Update - MarketBeat
HC Wainwright Issues Optimistic Estimate for AKRO Earnings - Defense World
Akero Therapeutics (NASDAQ:AKRO) Given New $75.00 Price Target at HC Wainwright - MarketBeat
Akero Therapeutics senior VP sells $48,090 in stock By Investing.com - Investing.com South Africa
Boston Pharma Plays Catch Up To Akero, 89bio In MASH - Citeline News & Insights
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Stockholders to Learn More About the Investigation - Markets Insider
Akero Therapeutics senior VP sells $48,090 in stock - Investing.com India
Akero Therapeutics Executives Sell Shares - TradingView
Akero therapeutics COO Jonathan Young sells $2.24 million in stock By Investing.com - Investing.com UK
Y Intercept Hong Kong Ltd Has $249,000 Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World
Akero Therapeutics, Inc. (NASDAQ:AKRO) Short Interest Up 32.0% in February - Defense World
Akero Therapeutics (NASDAQ:AKRO) Announces Quarterly Earnings Results, Misses Estimates By $0.01 EPS - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Investors to Inquire about Securities Investigation - Markets Insider
Is Agilon Health (AGL) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Akero Therapeutics stock target raised to $75 by H.C. Wainwright - Investing.com India
Akero Therapeutics, Inc. (NASDAQ:AKRO) Stake Lifted by Rhumbline Advisers - Defense World
Why Akero Therapeutics, Inc. (AKRO) is Skyrocketing So Far in 2025 - MSN
Akero Therapeutics (AKRO) to Release Earnings on Friday - MarketBeat
Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025 - Insider Monkey
Akero Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Akero Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
3 Mid-Caps Worth Watching Closely in March - MarketBeat
Akero Therapeutics, Inc. SEC 10-K Report - TradingView
Akero Therapeutics Q4 Loss Unchanged -February 28, 2025 at 07:27 am EST - Marketscreener.com
Earnings Flash (AKRO) Akero Therapeutics Posts Q4 Total Operating Expenses $78M - Marketscreener.com
Earnings Flash (AKRO) Akero Therapeutics Posts Q4 Loss $-0.99 Per Share, vs. FactSet Est of $-1.14 - Marketscreener.com
Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides - The Bakersfield Californian
Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire
Can Akero's Breakthrough Cirrhosis Reversal Results Reshape MASH Treatment Landscape? - StockTitan
IMMINENT AKRO DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Akero Therapeutics, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
Is Akero Therapeutics Inc. (AKRO) the Best Performing Mid Cap Stock to Buy According to Analysts? - MSN
Akero Therapeutics (AKRO) Projected to Post Quarterly Earnings on Thursday - Defense World
Madrigal’s Rezdiffra Continues Its Solid Launch - Scrip
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):